Lumos Diagnostics HoldingsASX:LDX 31 EBIT per Share is A$-0.02 as of Dec. 2025. GuruFocus rates ASX:LDX with a GF Score™ of 31/100 and a GF Value™ of A$0.02 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 690 Medical Devices & Instruments companies, Lumos Diagnostics Holdings ranks better than 90.43% on this metric.
Lumos Diagnostics Holdings's EBIT per Share for the
six
months ended in Dec. 2025 was A$-0.01.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.02.
During the past 3 years, the average EBIT per Share Growth Rate was 54.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Lumos Diagnostics Holdings's EBIT per Share or its related term are showing as below:
ASX:LDX'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 54 Med: 54 Max: 54
Current: 54
During the past 4 years, the highest 3-Year average EBIT per Share Growth Rate of Lumos Diagnostics Holdings was 54.00% per year. The lowest was 54.00% per year. And the median was 54.00% per year.
ASX:LDX's 3-Year EBIT Growth Rate is ranked better than 90.43% of 690
companies
in the Medical Devices & Instruments industry
Industry Median: 9.5
vs ASX:LDX: 54.00
Lumos Diagnostics Holdings (ASX:LDX) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Lumos Diagnostics Holdings EBIT per Share Related Terms
Lumos Diagnostics Holdings EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.02
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lumos Diagnostics Holdings (ASX:LDX) has a EBIT per Share of A$-0.02 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Lumos Diagnostics Holdings and its competitors. According to the industry distribution chart, Lumos Diagnostics Holdings ranks #66 out of 690 companies in the Medical Devices & Instruments industry, placing it in the top 9.6%.
Is Lumos Diagnostics Holdings' EBIT per Share too high?
Lumos Diagnostics Holdings' current EBIT per Share is A$-0.02. Based on the distribution chart, Lumos Diagnostics Holdings ranks #66 out of 690 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Lumos Diagnostics Holdings has a GF Score™ of 31/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lumos Diagnostics Holdings' EBIT per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Lumos Diagnostics Holdings ranks #66 out of 690 companies for EBIT per Share. This places Lumos Diagnostics Holdings in the top 10% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 9.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.50, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Lumos Diagnostics Holdings and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lumos Diagnostics Holdings's current EBIT per Share is A$-0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumos Diagnostics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Lumos Diagnostics Holdings (ASX:LDX) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.02, compared to a current price of A$0.11 — trading 425% above its estimated fair value. The current EBIT per Share is A$-0.02. Lumos Diagnostics Holdings' overall GF Score™ is 31/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Lumos Diagnostics Holdings (ASX:LDX), the current EBIT per Share is A$-0.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lumos Diagnostics Holdings (ASX:LDX) Overvalued in 2026?
Based on GuruFocus' analysis, Lumos Diagnostics Holdings stock appears to be overvalued.
The current stock price of A$0.11 is trading 425% above its estimated GF Value™ of A$0.02.
GuruFocus considers Lumos Diagnostics Holdings to be Significantly Overvalued.
Key valuation signals for ASX:LDX:
EBIT per Share: A$-0.02
GF Value™: A$0.02 vs. price of A$0.11 (425% above fair value)
No single metric tells the full story. See the ASX:LDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lumos Diagnostics Holdings Ltd is engaged in the development, manufacture, and distribution of point-of-care diagnostic (POC) tests and associated readers for analysis of POC diagnostic tests. The group is dedicated to providing contract research and development services, focusing on the innovation, development, manufacturing, and commercialization of point-of-care diagnostic solutions for both clinical and consumer applications. It generates maximum revenue from commercial services and solutions relating to POC diagnostic tests. The group has one operating segment, which is the provision of point-of-care diagnostics goods and services. The Company operates in two geographical regions, the United States and Australia and the majority of revenue is generated from the United States.
31GF Score
Get the complete analysis for ASX:LDX
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:LDX has been successfully added to your 
